Clinical Trial Update: GYNGHER - HER2 Expression in Gynecological Malignancies: a Brazilian Cohort

View source ↗

Summary

AstraZeneca’s GYNGHER study is a Brazilian cohort evaluating HER2 expression in gynecologic cancers, and the trial is currently not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gynecologic Cancers

Snippet

Sponsor: AstraZeneca | Conditions: Gynaecological Cancers | Status: NOT_YET_RECRUITING